Literature DB >> 7945430

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.

V W Ruiz van Haperen1, G Veerman, E Boven, P Noordhuis, J B Vermorken, G J Peters.   

Abstract

2',2'-Difluorodeoxycytidine (Gemcitabine, dFdC) is a relatively new deoxycytidine antimetabolite, with established activity against ovarian cancer and non-small-cell lung cancer. dFdC is assumed to exert its antitumour effect mainly by incorporation of the triphosphate dFdCTP into DNA. We determined the sensitivity to dFdC of six cell lines derived from solid tumours; two ovarian carcinoma (A2780 and OVCAR-3), two colon carcinoma (WiDr and C26-10) and two squamous cell carcinoma cell lines (UM-SCC-14C and UM-SCC-22B). In vitro sensitivity to dFdC was strongly time dependent. Under all conditions A2780 was the most sensitive cell line with an IC50 (the concentration of dFdC causing 50% growth inhibition) of 31 and 0.6 nM at 1 and 48 hr exposure, respectively. WiDr and C26-10 cells were relatively insensitive, with IC50s of 468 and 1133 nM, respectively, at 1 hr exposure, but of 11 and 6 nM at 48 hr exposure. Accumulation of the triphosphate dFdCTP was also time dependent. After 4 hr exposure to 10 microM dFdC, A2780, WiDr and C26-10 cells accumulated 223, 136 and 267 pmol/10(6) cells, respectively; after 24 hr exposure they accumulated 1045, 619 and 617 pmol/10(6) cells, respectively. A2780 cells retained the high dFdCTP concentration longer than 24 hr. For comparison purposes we also studied dFdCTP kinetics in the corresponding solid tumours, showing the same sensitivity pattern as the cell lines. In general, sensitivity to dFdC in vitro related with dFdCTP accumulation and retention, but in vivo this relation was less clear. Unexpectedly, remarkable in vitro and in vivo changes were observed in the ribonucleotide pools. The most predominant in vitro cell line dependent changes were a decrease in CTP concentrations, accompanied by an increase in UTP and GTP concentrations. In vivo CTP, UTP and GTP pools increased in all tumours. In conclusion, in this study we demonstrate that dFdCTP is accumulated and retained in solid tumours and cell lines. dFdCTP is not only important as a DNA precursor, but also appears to interfere with normal ribonucleotide metabolism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945430     DOI: 10.1016/0006-2952(94)90554-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

1.  Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.

Authors:  C F Pollera; A Ceribelli; M Crecco; C Oliva; F Calabresi
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

3.  No evidence of gemcitabine accumulation during weekly administration.

Authors:  S M de Lange; K van der Born; J R Kroep; H A Jensen; P Pfeiffer; A Cleverly; C J van Groeningen; G J Peters
Journal:  Eur J Clin Pharmacol       Date:  2005-11-10       Impact factor: 2.953

4.  The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Authors:  Nadim Bou Zgheib; Yin Xiong; Douglas C Marchion; Elona Bicaku; Hye Sook Chon; Xiaomang Ba Stickles; Entidhar Al Sawah; Patricia L Judson; Ardeshir Hakam; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Christopher L Cubitt; Dung Tsa Chen; Johnathan M Lancaster
Journal:  Int J Oncol       Date:  2012-04-26       Impact factor: 5.650

5.  Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate.

Authors:  Wei Chu; Pengqian Tian; Ning Ding; Qing Cai; Jinlong Li; Xuezhi Zhuo; Zhaohui Tang; Jingxin Gou; Tian Yin; Yu Zhang; Haibing He; Xing Tang
Journal:  Pharm Res       Date:  2018-10-11       Impact factor: 4.200

Review 6.  Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Authors:  S A Johnson
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

7.  Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.

Authors:  Marina Gálvez-Peralta; Nga T Dai; David A Loegering; Karen S Flatten; Stephanie L Safgren; Jill M Wagner; Matthew M Ames; Larry M Karnitz; Scott H Kaufmann
Journal:  Mol Pharmacol       Date:  2008-05-28       Impact factor: 4.436

8.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Authors:  Kristopher K Frese; Albrecht Neesse; Natalie Cook; Tashinga E Bapiro; Martijn P Lolkema; Duncan I Jodrell; David A Tuveson
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

9.  Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics.

Authors:  Neslihan Aygun Kocabas; Pinar Aksoy; Linda L Pelleymounter; Irene Moon; Jeong-Seon Ryu; Judith A Gilbert; Oreste Ezequel Salavaggione; Bruce W Eckloff; Eric D Wieben; Vivien Yee; Richard M Weinshilboum; Matthew M Ames
Journal:  Drug Metab Dispos       Date:  2008-06-12       Impact factor: 3.922

10.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.